Abstract
Radioimmunotherapy with radiolabeled anti-CD20 antibodies is a promising new treatment approach for low-grade non-Hodgkin's lymphoma. However, the administration of radiolabeled antibodies presents some added complexity. At the University of Nebraska Medical Center (Omaha, NE), an institutional model has been developed that ensures the efficient and safe delivery of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, South San Francisco, CA and GlaxoSmithKline, Philadelphia, PA). An integrated, multidisciplinary treatment team is responsible for managing all aspects of treatment. Using this model, it is possible to administer tositumomab and iodine I 131 tositumomab safely and effectively in the outpatient setting. Patients can usually be released immediately after treatment. Guidelines and instructions for patient release have been developed and validated and are provided herein. These instructions ensure that radiation exposure of family members and caregivers who are exposed to the patient is maintained as low as reasonably achievable and well within regulatory limits.
| Original language | English |
|---|---|
| Pages (from-to) | 39-49 |
| Number of pages | 11 |
| Journal | Seminars in Oncology |
| Volume | 30 |
| Issue number | 2 SUPPL. 4 |
| State | Published - Apr 2003 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
Cite this
Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab. / Hohenstein, Maribeth A.; Augustine, Samuel C.; Rutar, Frank; Vose, Julie M.
In: Seminars in Oncology, Vol. 30, No. 2 SUPPL. 4, 04.2003, p. 39-49.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab
AU - Hohenstein, Maribeth A.
AU - Augustine, Samuel C.
AU - Rutar, Frank
AU - Vose, Julie M.
PY - 2003/4
Y1 - 2003/4
N2 - Radioimmunotherapy with radiolabeled anti-CD20 antibodies is a promising new treatment approach for low-grade non-Hodgkin's lymphoma. However, the administration of radiolabeled antibodies presents some added complexity. At the University of Nebraska Medical Center (Omaha, NE), an institutional model has been developed that ensures the efficient and safe delivery of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, South San Francisco, CA and GlaxoSmithKline, Philadelphia, PA). An integrated, multidisciplinary treatment team is responsible for managing all aspects of treatment. Using this model, it is possible to administer tositumomab and iodine I 131 tositumomab safely and effectively in the outpatient setting. Patients can usually be released immediately after treatment. Guidelines and instructions for patient release have been developed and validated and are provided herein. These instructions ensure that radiation exposure of family members and caregivers who are exposed to the patient is maintained as low as reasonably achievable and well within regulatory limits.
AB - Radioimmunotherapy with radiolabeled anti-CD20 antibodies is a promising new treatment approach for low-grade non-Hodgkin's lymphoma. However, the administration of radiolabeled antibodies presents some added complexity. At the University of Nebraska Medical Center (Omaha, NE), an institutional model has been developed that ensures the efficient and safe delivery of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, South San Francisco, CA and GlaxoSmithKline, Philadelphia, PA). An integrated, multidisciplinary treatment team is responsible for managing all aspects of treatment. Using this model, it is possible to administer tositumomab and iodine I 131 tositumomab safely and effectively in the outpatient setting. Patients can usually be released immediately after treatment. Guidelines and instructions for patient release have been developed and validated and are provided herein. These instructions ensure that radiation exposure of family members and caregivers who are exposed to the patient is maintained as low as reasonably achievable and well within regulatory limits.
UR - http://www.scopus.com/inward/record.url?scp=0345532410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0345532410&partnerID=8YFLogxK
M3 - Review article
VL - 30
SP - 39
EP - 49
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 2 SUPPL. 4
ER -